p-amidinophenyl cinnamate | 789440-73-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: p-amidinophenyl cinnamate
• 英文别名: 4-Amidinophenyl cinnamate；(4-carbamimidoylphenyl) (E)-3-phenylprop-2-enoate
• CAS: 789440-73-9
• 化学式: C₁₆H₁₄N₂O₂
• 分子量: 266.299
• InChiKey: SYMNKMKOTLVJCE-IZZDOVSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Enzyme derivatives for use in the treatment of venous thrombosis, compositions containing them and their preparation
  申请人：BEECHAM GROUP PLC

  公开号：EP0009879A1

  公开（公告）日：1980-04-16

  A pharmaceutical composition which comprises a pharmaceutically acceptable carrier together with an in vivo fibrinolytic enzyme as defined herein wherein the catalytic site essential for fibrinolytic activity is blocked by a group which is removable by hydrolysis at a rate such that the pseudo-first order rate constant for hydrolysis is in the range 10-6 sec-1 to 10-3sec-1 in isotonic aqueous media at pH 7.4 at 37°C; is useful in the treatment of venous thrombosis.

  一种药物组合物，它包括药学上可接受的载体和本文定义的体内纤维蛋白溶解酶，其中纤维蛋白溶解活性所必需的催化位点被一个基团阻断，该基团可通过水解去除，水解的假一阶速率常数在 10-6 秒-1 到 10-3 秒-1 之间，在 37°C pH 值为 7.4 的等渗水介质中；该药物组合物可用于治疗静脉血栓。
• Enzyme derivatives, and their preparation
  申请人：BEECHAM GROUP PLC

  公开号：EP0028489A1

  公开（公告）日：1981-05-13

  An enzyme derivative comprises a binary complex between streptokinase and plasminogen in which the catalytic site essential for fibrinolytic activity is blocked by a group which is removable by hydrolysis such that the pseudo-first order rate constant for hydrolysis of the derivative is in the range 10-6sec-1to 10-3 sec-1 in isotonic aqueous media at pH 7.4 at 37°C, and is useful in the treatment of venous thrombosis.

  一种酶衍生物包括链激酶和纤溶酶原之间的二元复合物，其中对纤维蛋白溶解活性至关重要的催化位点被一个基团阻断，该基团可通过水解作用移除，因此在 37°C pH 值为 7.4 的等渗水介质中，该衍生物水解的假一阶速率常数在 10-6 秒-1 至 10-3 秒-1 之间，可用于治疗静脉血栓。
• ENZYME DERIVATIVES
  申请人：BEECHAM GROUP PLC

  公开号：EP0151593A1

  公开（公告）日：1985-08-21
• Compositions and methods for treatment of viral diseases
  申请人：Johansen Lisa M.

  公开号：US20080161324A1

  公开（公告）日：2008-07-03

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.